Here, we analyzed the treatment outcomes in DLBCL patients and discovered that CTLA4 genetic variants may have clinical impact on the treatment outcome in DLBCL patients treated with the current CD19 CAR-T cell therapies. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.